You are here

Article Text

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer
  1. H. T. See*,
  2. D. A. Thomas†,
  3. C. Bueso-Ramos‡ and
  4. J. Kavanagh*
  1. * Departments of Gynecological Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
  2. † Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
  3. ‡ Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: John Kavanagh, MD, Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1364, Houston, TX 77030, USA. Email: jkavanag{at}mdanderson.org

Abstract

The occurrence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported after treatment with cytotoxic alkylating agent–based chemotherapy for solid tumors. We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia. The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade. Monitoring of the long-term outcome of paclitaxel- and platinum-based regimens is warranted, particularly with regard to monitoring the development of secondary MDS and/or AML. The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.

  • erythroleukemia
  • ovarian cancer
  • paclitaxel

https://doi.org/10.1136/ijgc-00009577-200602001-00038

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.